Fourteen healthy adult Beagle dogs were included in this clinical study. Dogs randomly allocated to two study groups were treated on day 0 with a spot-on containing imidacloprid/moxidectin at the maximum approved dosage of 25 mg imidacloprid/kg bodyweight (bw) + 6.25 mg moxidectin/kg bw. Group 1 was treated at the same time orally with tablets containing emodepside/ praziquantel at the maximum approved dosage of 1.9 mg emodepside/kg bw + 9.4 mg praziquantel/kg bw. Group 2 was treated on day 8 with emodepside/praziquantel tablets at the same dosage. These two different treatment scenarios were selected to compare a simultaneous treatment with a consecutive treatment. In the consecutive treatment an 8-day interval was chosen to ensure overlapping peak serum concentrations of emodepside and moxidectin. Dogs were fed directly after treatment. Profound safety assessments were performed preand post-treatment. Blood samples were drawn preand post-treatment to evaluate the hematology and clinical chemistry profile as well as the serum levels of moxidectin and emodepside. Neither compound-related adverse reactions nor treatment-related changes in the blood hematology or chemistry profile were seen. In this study reported here, it was clearly demonstrated that the concomitant treatment of both products applied either simultaneously or consecutively did not lead to any clinical nor laboratory abnormalities in adult Beagle dogs.